Table 1.
Patient’s characteristics and Treatments, N = 156.
| Characteristics | Statisticsa | |
|---|---|---|
| Age, years | Mean (SD) | 66.5 (± 10.3) |
| <75 | 129 (82.7) | |
| ≥75 | 27 (17.3) | |
| Months from cancer diagnosis | ≤3 | 28 (18.0) |
| (3–12] | 32 (20.5) | |
| >12 | 96 (61.5) | |
| Sex | Female | 69 (44.2) |
| Male | 87 (55.8) | |
| Histology | Adenocarcinoma | 132 (84.6) |
| Squamous carcinoma | 10 (6.4) | |
| SCLC | 9 (5.8) | |
| LCNEC | 1 (0.6) | |
| Other | 4 (2.6) | |
| Current stage | Metastatic | 136 (87.7) |
| Locally advanced | 14 (9.0) | |
| Early | 6 (3.9) | |
| ECOG PS | 0 | 48 (30.8) |
| 1 | 108 (69.2) | |
| Smoking status | Never | 46 (29.5) |
| Formerb | 75 (48.1) | |
| Current | 35 (22.4) | |
| Comorbidities | Cardio-pulmonary | 114 (73.1) |
| Region | Lombardia | 107 (69.0) |
| Other regions | 49 (31.0) | |
| Previous surgery/pulmonary RT | 73 (46.8) | |
| Therapy setting | Metastatic | 140 (89.7) |
| Adjuvant/Neo-adjuvant | 10 (7.7) | |
| CT/RT | 6 (3.9) | |
| Therapy | No therapy | 18 (11.5) |
| TKI | 55 (35.3) | |
| Intravenous | 83 (53.2) | |
| CT | 30 (19.2) | |
| IO | 35 (22.4) | |
| CT+IO | 15 (9.6) | |
| CT+RT | 3 (1.9) |
a
Statistics are: mean (± SD) for age, N (%) otherwise.
b
Quit smoking for at least 12 months.
TKI, tyrosine kinase inhibitor; CT, chemotherapy; IO, immunotherapy; RT, radiotherapy; SCLC, small cell lung cancer; LCNEC, large cell neuroendocrine carcinoma; SD, standard deviation.